Should CDK4/6 inhibitors replace chemotherapy in HR+ /HER2− metastatic breast cancer with visceral crisis? Evaluating the emerging evidence
Open Access
- 2 June 2025
- journal article
- review article
- Published by Springer Nature in Discover Oncology
- Vol. 16 (1) , 1-10
Abstract
The traditional approach to hormone receptor-positive (HR +)/HER2− negative metastatic breast cancer with visceral crisis has been cytotoxic chemotherapy, based on the assumption of more rapid efficacy. However, emerging evidence challenges this long-standing paradigm. This perspective critically evaluates recent data comparing CDK4/6 inhibitors plus endocrine therapy with chemotherapy in this challenging clinical scenario. Three recent clinical trials (RIGHT Choice, PADMA, and ABIGAIL) demonstrate improved progression-free survival and comparable response rates with CDK4/6 inhibitors versus chemotherapy in patients with aggressive disease features. Additionally, a direct retrospective comparison by Behrouzi et al. showed significantly better outcomes across all endpoints (TTF, PFS, and OS) with CDK4/6 inhibitors compared to weekly paclitaxel, with similar time to first improvement in organ dysfunction (3.9 vs 3.6 weeks). Supporting real-world evidence suggests a 5-month overall survival advantage with CDK4/6 inhibitors in visceral crisis. These convergent findings raise important questions about current treatment guidelines, which still recommend chemotherapy as the standard approach. The article examines the quality of available evidence, discusses potential reasons for reluctance to change practice patterns, and addresses remaining unanswered questions. While acknowledging limitations in the evidence base, including selection biases and lack of long-term survival data from randomized trials, this perspective proposes that CDK4/6 inhibitors represent a viable alternative to chemotherapy for carefully selected patients with HR+ /HER2− metastatic breast cancer and visceral crisis. A thoughtful, patient-centered approach considering disease characteristics, prior therapies, and the need for rapid response should guide treatment decisions while we await more definitive evidence.Keywords
This publication has 10 references indexed in Scilit:
- 310P Quality of life with first-line ET + palbociclib vs standard mono-chemotherapy in high risk HER2-/HR+ mBC and indication for chemotherapy in the PADMA studyESMO Open, 2025
- Inavolisib-Based Therapy in PIK3CA -Mutated Advanced Breast CancerNew England Journal of Medicine, 2024
- LBA23 ABIGAIL: Randomized phase II study of abemaciclib plus endocrine therapy (ET) with or without a short course of induction paclitaxel in patients (pts) with previously untreated HR-positive/HER2-negative advanced breast cancer (HR+/HER2- ABC) with aggressive disease criteriaAnnals of Oncology, 2024
- Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast CancerJournal of Clinical Oncology, 2024
- 6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)The Breast, 2024
- A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitorsNature Cancer, 2024
- CDK4/6 inhibitors versus weekly paclitaxel for treatment of ER+/HER2- advanced breast cancer with impending or established visceral crisisBreast Cancer Research and Treatment, 2023
- Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trialEuropean Journal of Cancer, 2023
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database.Journal of Clinical Oncology, 2021